ClinicalTrials.gg
RecruitingNCT07285135Updated Oct 27, 2026

Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease

An interventional study of Glycine and Placebo in Metabolic Dysfunction Associated Fatty Liver Disease, sponsored by Singapore General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Singapore General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Oct 27, 2026Now RecruitingFirst site in Singapore+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
21 Years to 70 Years
Sex
All
01

Study summary

This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves liver health and metabolic function.

The study consists of two components. The first is a cross-sectional case-control study comparing urinary acylglycine concentrations and other glycine-dependent metabolic parameters between 60 participants with MASLD and 30 healthy controls. The second is a randomized, double-blind, placebo-controlled trial in which 60 participants with MASLD will receive either oral glycine supplementation (9 g/day) or placebo for 26 weeks.

The primary outcomes are differences in urinary acylglycine concentrations between participants with MASLD and healthy controls, and changes in hepatic fat content measured by MRI-PDFF and urinary acylglycine concentrations following supplementation. Additional assessments will evaluate amino acid metabolism, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers. Participants will undergo baseline, Week 12, and Week 26 assessments to evaluate metabolic changes and treatment responses.

Read the detailed description

This study consists of two complementary components designed to investigate abnormalities in glycine-dependent metabolic pathways in metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate the effects of dietary glycine supplementation on liver health and metabolic function.

Component 1: Cross-sectional case-control study

A total of 60 participants with MASLD and 30 healthy controls will undergo baseline clinical, imaging, and metabolic assessments. The primary objective is to compare urinary acylglycine concentrations between participants with MASLD and healthy controls to identify abnormalities in glycine conjugation metabolism. Additional metabolic profiling will characterize differences in circulating amino acids and other glycine-dependent metabolic pathways.

Healthy controls will complete their participation following the baseline assessments and will not receive dietary supplementation.

Component 2: Randomized controlled trial

The 60 participants with MASLD will be randomized in a 1:1 ratio to receive either oral glycine supplementation (9 g/day) or matching placebo for 26 weeks. The study will be double-blinded, with participants and investigators masked to treatment allocation.

The primary outcomes of the randomized trial are changes in hepatic fat content, measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF), and urinary acylglycine concentrations following 26 weeks of supplementation.

Additional outcomes will evaluate changes in circulating glycine and other amino acid concentrations, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers, including vitamin B12, folate, and homocysteine. These measurements will help characterize the metabolic effects of glycine supplementation and explore potential mechanisms underlying changes in liver health.

Participants will undergo baseline metabolic assessments before randomization, an interim assessment at Week 12 ± 4 weeks, and a final assessment at Week 26 ± 4 weeks. Assessments will include abdominal MRI, clinical and anthropometric measurements, blood and urine sampling, and comprehensive metabolic profiling.

Together, the two components aim to identify glycine-dependent metabolic abnormalities associated with MASLD and determine whether dietary glycine supplementation can improve hepatic steatosis and related metabolic disturbances.

02

Conditions studied

  • Metabolic Dysfunction Associated Fatty Liver Disease

Browse trials for

Keywords

  • Fatty liver
  • Randomized controlled trial
  • glycine supplements
03

In context

Fatty Liver

666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.

This study's planned enrollment of 90 is above the median of 60 across 434 interventional studies indexed under Fatty Liver.

Browse Fatty Liver studies →

Lead sponsor

Singapore General Hospital is the lead sponsor of 270 studies on the registry; 57 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Oct 27, 2026. See what changed

Ages eligible
21 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects:

  1. Age 21-70 years
  2. Ability to provide .

MASLD group:

  1. Hepatic steatosis on MRI
  2. of 25-50 kg/m2

Controls:

  1. Absence of hepatic steatosis on MRI
  2. BMI of 18.5-24.9 kg/m2
  3. No chronic disease
  4. No long-term medications

Exclusion criteria

Exclusion Criteria:

  1. Uncontrolled diabetes ( > 8%)
  2. Type 1 Diabetes Mellitus
  3. anemia ( \< 10 g/dL)
  4. Chronic liver disorders (except MASLD) such as , , Wilson's disease, hemochromatosis, hepatitis, chronic cholestatic disorders, and liver cirrhosis
  5. Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
  6. (GFR \< 30 ml/min)
  7. Serum (ALT) > 3x (ULN)
  8. Serum aspartate transaminase (AST) > 3x ULN
  9. Liver cirrhosis
  10. Significant alcohol consumption (> 20g/day for women and >30g/day for men)
  11. Pregnancy
  12. Uncontrolled thyroid disease
  13. Previous bariatric surgery
  14. Weight loss > 5% in the past 1 month
  15. Metallic implants (including incompatible pacemakers, AICD, metallic heart valves) or other to MRI
  16. Claustrophobia
  17. Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other, or family members)
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Glycine

    9g per day of glycine in capsules

    Dietary Supplement: Glycine

  • Placebo comparator
    Placebo

    Microcrystalline cellulose in capsules

    Dietary Supplement: Placebo

  • No intervention
    Healthy Controls

    Healthy individuals without hepatic steatosis on MRI who undergo baseline clinical, imaging and metabolic assessments. Participants complete the study after Visit 3 and receive neither glycine nor placebo.

Interventions

  • Dietary supplementGlycine

    9g/day of glycine in capsules

  • Dietary supplementPlacebo

    Microcrystalline cellulose in identifically-looking capsules

06

What researchers measure

Primary outcomes

  1. Difference in urinary acylglycine concentrations between MASLD participants and healthy controls

    Urinary concentrations of acetylglycine, isobutyrylglycine, tigylglycine, isovalerylglycine, hexanoylglycine, octanoylglycine, and benzoylglycine will be quantified. Concentrations will be normalized to urinary creatinine and expressed as mmol/mol creatinine. The concentrations will be compared between participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and healthy controls to evaluate differences in glycine conjugation metabolism.

    Time frame: Baseline

  2. Change in hepatic proton density fat fraction (MRI-PDFF) from baseline to 26 weeks

    Hepatic fat content will be quantified using magnetic resonance imaging proton density fat fraction (MRI-PDFF). Changes over time will be assessed using mixed-effects models incorporating baseline, Week 12, and Week 26 measurements. The primary comparison will be the between-group difference in change from baseline to Week 26.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  3. Changes in urinary acylglycine concentrations following dietary glycine supplementation.

    Urinary concentrations of acetylglycine, isobutyrylglycine, tigylglycine, isovalerylglycine, hexanoylglycine, octanoylglycine, and benzoylglycine (hippurate) will be quantified. Concentrations will be normalized to urinary creatinine and expressed as mmol/mol creatinine. Individual metabolite concentrations will be evaluated separately. Changes over time will be assessed using mixed-effects models incorporating baseline, Week 12, and Week 26 measurements. The primary comparison will be the between-group difference in change from baseline to Week 26.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

Secondary outcomes

  1. Proportion achieving greater than 30% relative reduction in hepatic MRI-PDFF

    The proportion of participants achieving greater than 30% relative reduction in hepatic MRI-PDFF from baseline to Week 26 will be compared between the glycine and placebo groups. Relative reduction will be calculated as \[(baseline MRI-PDFF - Week 26 MRI-PDFF) / baseline MRI-PDFF\] × 100.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  2. Change in glutathione concentrations following dietary glycine supplementation.

    Reduced glutathione (GSH), oxidized glutathione (GSSG), and/or total glutathione concentrations in mmol/L will be measured in blood-derived samples. Baseline concentrations will be compared between participants with MASLD and healthy controls. Changes from baseline to Weeks 12 and 26 will be evaluated between the glycine and placebo groups to investigate the effects of supplementation on glutathione metabolism.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  3. Change in sleep quality following dietary glycine supplementation.

    Sleep quality will be evaluated using the Pittsburgh Sleep Quality Index (PSQI). Changes in the PSQI global score from baseline to Weeks 12 and 26 will be compared between participants receiving glycine supplementation and placebo. Scores range from 0 to 21, with higher scores indicating poorer sleep quality.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  4. Change in serum alanine aminotransferase (ALT) following glycine supplementation

    Serum alanine aminotransferase (ALT), in U/L, will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. ALT will also be assessed at Week 12.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  5. Change in serum alanine aspartate aminotransferase (AST) following glycine supplementation

    Serum aspartate aminotransferase (AST), in U/L, will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. AST will also be assessed at Week 12.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  6. Change in plasma glucose concentration following glycine supplementation

    Fasting plasma glucose (mmol/L) will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. Fasting serum glucose will also be assessed at Week 12.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  7. Change in serum insulin concentration following glycine supplementation

    Fasting serum insulin (U/L) will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. Fasting serum insulin will also be assessed at Week 12.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

  8. Change in HbA1C following glycine supplementation

    HbA1C (%) will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. HbA1C will also be assessed at Week 12.

    Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication

Time frame: Beginning 3 months and ending 3 years after the publication of results

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jul 2028, 32 months after the start.

Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 32 months is above that.

Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Nov 2025, on Oct 27, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Dec 16, 2025
StartActual
Nov 1, 2025was Dec 2025
Primary completionEst.
Jul 2028
CompletionEst.
Jan 2029
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
1 site added — first site in Singapore
Show site
  • Singapore General Hospital · Singapore, Singapore
Oct 27, 2026
Start date
Dec 2025→Nov 1, 2025 (actual)
Oct 27, 2026
Enrollment
60→90
Oct 27, 2026
Eligibility
1 exclusion criterion removed
What changed in the criteria
Exclusion criteria
  • RemovedReceiving weight loss medications or GLP-1 receptor agonists
Oct 27, 2026
Interventions
Arms added: Healthy Controls
Oct 27, 2026
Primary outcomes
3 added, 2 removed
What changed in the outcomes
  • AddedDifference in urinary acylglycine concentrations between MASLD participants and healthy controlsTime frame: Baseline
  • AddedChange in hepatic proton density fat fraction (MRI-PDFF) from baseline to 26 weeksTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChanges in urinary acylglycine concentrations following dietary glycine supplementation.Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • RemovedChanges in hepatic Magnetic Resonance Imaging-Proton Density Fat Fraction and concentrations of acylglycines, glutathione, cytokines, oxidative stress markers, and 1-carbon cycle metabolites from baseline to 26 weeksTime frame: From the initiation to end of the treatment at 26 weeks
  • RemovedDifferences in concentrations of acylglycines, glutathione, cytokines, oxidative stress markers, and 1-carbon cycle metabolites between subjects with MASLD and controlsTime frame: From enrollment to the completion of baseline metabolic assessment (within 8 weeks)
Oct 27, 2026
Secondary outcomes
8 added
What changed in the outcomes
  • AddedProportion achieving greater than 30% relative reduction in hepatic MRI-PDFFTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChange in glutathione concentrations following dietary glycine supplementation.Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChange in sleep quality following dietary glycine supplementation.Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChange in serum alanine aminotransferase (ALT) following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChange in serum alanine aspartate aminotransferase (AST) following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChange in plasma glucose concentration following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChange in serum insulin concentration following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
  • AddedChange in HbA1C following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Singapore
    Show site
    • Singapore General Hospital · Singapore, Singapore
    Start date Dec 2025→Nov 1, 2025 (now actual)
    Enrollment 60→90
    Eligibility 1 exclusion criterion removed
    What changed in the criteria
    Exclusion criteria
    • RemovedReceiving weight loss medications or GLP-1 receptor agonists
    Primary outcomes 3 added, 2 removed
    What changed in the outcomes
    • AddedDifference in urinary acylglycine concentrations between MASLD participants and healthy controlsTime frame: Baseline
    • AddedChange in hepatic proton density fat fraction (MRI-PDFF) from baseline to 26 weeksTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChanges in urinary acylglycine concentrations following dietary glycine supplementation.Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • RemovedChanges in hepatic Magnetic Resonance Imaging-Proton Density Fat Fraction and concentrations of acylglycines, glutathione, cytokines, oxidative stress markers, and 1-carbon cycle metabolites from baseline to 26 weeksTime frame: From the initiation to end of the treatment at 26 weeks
    • RemovedDifferences in concentrations of acylglycines, glutathione, cytokines, oxidative stress markers, and 1-carbon cycle metabolites between subjects with MASLD and controlsTime frame: From enrollment to the completion of baseline metabolic assessment (within 8 weeks)
    Secondary outcomes 8 added
    What changed in the outcomes
    • AddedProportion achieving greater than 30% relative reduction in hepatic MRI-PDFFTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChange in glutathione concentrations following dietary glycine supplementation.Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChange in sleep quality following dietary glycine supplementation.Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChange in serum alanine aminotransferase (ALT) following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChange in serum alanine aspartate aminotransferase (AST) following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChange in plasma glucose concentration following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChange in serum insulin concentration following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    • AddedChange in HbA1C following glycine supplementationTime frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
    Interventions Arms added: Healthy Controls
    + 2 other changes: description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07285135
Responsible party
Sponsor
First posted
Dec 16, 2025
Start date
Nov 1, 2025
Primary completion
Jul 2028 (estimated)
Completion
Jan 2029 (estimated)
Last update
Oct 27, 2026

Study contacts

Hong Chang Tan, MD PhD
Contact
tan.hong.chang@singhealth.com.sg
+65 63214658

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycine

Start the discussion